DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B Stock

Certificat

DE000ME79EK7

Real-time Bid/Ask 11:25:04 2024-07-03 EDT
89.58 EUR / 89.63 EUR -0.92% Intraday chart for DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B
Current month-0.21%
1 month+2.10%
Date Price Change
24-07-03 89.56 -0.97%
24-07-02 90.44 -0.18%
24-07-01 90.6 -0.03%
24-06-28 90.63 +0.02%
24-06-27 90.61 -0.21%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 11:24 am

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME79EK
ISINDE000ME79EK7
Date issued 2024-01-22
Cap 100 $
Last trading day 2024-12-20
Maturity 2024-12-20 (170 Days)
Parity 1 : 1
Emission price 82.98
Emission volume N/A
Payment day 2024-12-31
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 30.21 %
Sideways yield 3.258 %
Sideways yield pa 6.994 %
Outperformance point 143.3 $
Break even 96.85 €
Highest since issue 90.8
Lowest since issue 80.12
Spread 0.06
Spread %0.07%
Distance Cap 37.42 $
Distance Cap %+27.23%
Max. earning 2.92
Max. earning % 3.258 %

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5 DKK
Average target price
952.2 DKK
Spread / Average Target
-4.16%
Consensus